Patents by Inventor Flavie Pouillot

Flavie Pouillot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phage therapy of infections
    Patent number: 11957724
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: April 16, 2024
    Assignee: ERYTECH PHARMA
    Inventors: Flavie Pouillot, Hélène Blois
  • Phage therapy
    Patent number: 11779617
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: October 10, 2023
    Assignee: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Helene Blois
  • PHAGE THERAPY
    Publication number: 20210228659
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: January 21, 2021
    Publication date: July 29, 2021
    Inventors: FLAVIE POUILLOT, HELENE BLOIS
  • PHAGE THERAPY OF E COLI INFECTIONS
    Publication number: 20210060100
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 4, 2021
    Inventors: FLAVIE POUILLOT, HÉLÈNE BLOIS
  • Phage therapy of infections
    Patent number: 10918680
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: February 16, 2021
    Assignee: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Hélène Blois
  • Phage therapy
    Patent number: 10898530
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 26, 2021
    Assignee: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Helene Blois
  • Phage therapy of infections
    Patent number: 10260051
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: April 16, 2019
    Assignee: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Helene Blois
  • PHAGE THERAPY OF PSEUDOMONAS INFECTIONS
    Publication number: 20190002840
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 3, 2019
    Inventors: FLAVIE POUILLOT, HELENE BLOIS
  • Phage therapy of pseudomonas infections
    Patent number: 10077431
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: September 18, 2018
    Assignee: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Hélène Blois
  • PHAGE THERAPY
    Publication number: 20170319637
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 9, 2017
    Inventors: FLAVIE POUILLOT, HELENE BLOIS
  • PHAGE THERAPY OF E COLI INFECTIONS
    Publication number: 20170000831
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: January 9, 2015
    Publication date: January 5, 2017
    Inventors: FLAVIE POUILLOT, HÉLÈNE BLOIS
  • PHAGE THERAPY OF PSEUDOMONAS INFECTIONS
    Publication number: 20160264941
    Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
    Type: Application
    Filed: October 24, 2014
    Publication date: September 15, 2016
    Inventors: Flavie POUILLOT, Hélène BLOIS
  • Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof
    Patent number: 9029153
    Abstract: The present invention relates to a method for the reversible immobilization of lytic bacteriophages within their modified bacterial hosts. It relates more particularly to a method for modifying the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: May 12, 2015
    Assignee: Pherecydes Pharma
    Inventors: Flavie Pouillot, Francois Iris
  • MODIFICATION OF THE GENOME OF A LYTIC BACTERIOPHAGE BY IMMOBILIZING SAID BACTERIOPHAGE IN THE HOST BACTERIUM THEREOF
    Publication number: 20120040465
    Abstract: The present invention relates to a method for the reversible immobilization of lytic bacteriophages within their modified bacterial hosts. It relates more particularly to a method for modifying the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof.
    Type: Application
    Filed: April 27, 2010
    Publication date: February 16, 2012
    Applicant: PHERECYDES PHARMA
    Inventors: Flavie Pouillot, Francois Iris